antares pharma products

Antares' product sales in Q4 of $28.5 million set an all-time high, and more than doubled the $14.2 million in the prior-year period. Contact us at Antares Health Products Vitamin E TPGS. The study included a screening phase, a treatment titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. According to Teva, the Public Assessment Report for the decentralized procedure has been published and the product was filed in 17 countries, which addresses the majority of the market value in Europe. EWING, N.J., July 21, 2020 -- Antares Pharma, Inc. , a pharmaceutical technology company, announced the first commercialization of the Company’s multi-dose pen platform launched in... | December 15, 2020 Antares Pharma, Inc. (ATRS) is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company received FDA approval of its Abbreviated New Drug Application (“ANDA”) for 4 mg/0.5 mL and 6 mg/0.5 mL single-dose prefilled syringe auto-injectors, a generic equivalent to Imitrex® STATdose Pen®, in December 2015. Antares Pharma is collaborating with Teva on a VIBEX® auto injector pen containing epinephrine used for the treatment of severe allergic reactions (anaphylaxis). The NDA submission was accepted for standard review by the FDA and assigned a Prescription Drug User Fee Act (“PDUFA”) target date for completion of its review by October 20, 2017. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The results of these two studies formed the clinical basis of its NDA submission for XYOSTEDTM and are further discussed in the “Research and Development Programs” section below. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. The settlement allows Teva to commercialize their exenatide product in the U.S. beginning October 15, 2017 or earlier under certain circumstances. Antares Pharma has formed significant strategic alliances and partnership arrangements with industry leading pharmaceutical companies including Teva, AMAG, and Ferring Pharmaceuticals Inc. and Ferring B.V. (together “Ferring”). FIRST COMMERCIAL PRODUCT USING ANTARES PHARMA'S MULTI-DOSE PEN PLATFORM LAUNCHES IN EUROPE EWING, NJ, July 21, 2020--Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") ("the Company"), a pharmaceutical technology company, announced the first commercialization of the Company's multi- dose pen platform launched in Europe. The company’s revenue for the quarter stood at $40.0 billion. Yahoo is part of Verizon Media. Antares Pharma has strategic alliances and partnership arrangements with several pharmaceutic companies. Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products … Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Inject… Find out more about how we use your information in our Privacy Policy and Cookie Policy. Teva has advised it that they submitted a response to the CRL and are targeting a launch in early 2018. Based upon a written response the company received from the FDA related to its clinical development program for XYOSTEDTM, the company conducted an additional supplemental safety study QST-15-005. The company market and sell its proprietary product OTREXUP® (methotrexate) injection, which was launched in the U.S. in February 2014. You can change your choices at any time by visiting Your Privacy Controls. The Company's injection products include syringes and self-injection systems for patients with rheumatoid arthritis, psoriasis, migraine and cluster headache, needle-free and disposable pressure-assisted auto injectors for various purposes. TPGS has utility and a proven record of safety and efficacy in pharmaceutical, dietary supplement, food & beverage, personal care, animal nutrition and CBD and other botanical oil products. The company's testosterone injection Xyosted and chemotherapy Otrexup both delivered strong sales growth. EWING - Antares Pharma, Inc. (NASDAQ: ATRS) ('the Company'), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020. With its commercialization partner Teva, the company launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals. Our marketed products include Otrexup™, Sumatriptan autoinjector, Zoma-Jet and Gelnique, and are built on our proven auto injector and pen device platforms. Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. In 2016, the company announced that Teva had settled the patent litigation with AstraZeneca Pharmaceuticals, LP, AstraZeneca AB, and Amylin Pharmaceuticals, LLC (collectively “AstraZeneca”) relating to certain AstraZeneca U.S. patents and their drug, BYETTA® (exenatide). To date, Antares Pharma has received FDA approval for dosage strengths of 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg of OTREXUP®. Information about your device and internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. Antares' partnered product sales to Teva Pharmaceutical Industries, AMAG Pharmaceuticals, and Ferring Pharmaceuticals also increased year over year. In 2001 Dr. Sadowski became Vice President of the Company’s Devices Group where he led the conceptualization and development of the VIBEX mini-needle injection technology platform. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. The company also make reusable, needle-free injection devices that administer injectable drugs, which are currently marketed primarily through its partner Ferring, for use with human growth hormone, and have two gel-based products that are commercialized through its partners pursuant to licensing arrangements. In September 2016, the company announced the successful completion of the QST-15-005 study. According to AMAG, the study successfully demonstrated comparable bioavailability between subcutaneous injection of Makena® compared to intra muscular injection. Under a license, development and supply agreement, AMAG is responsible for the clinical development and preparation, submission and maintenance of all regulatory applications, the manufacture and supply of the drug, and the marketing, sale and distribution of the product. Antares Pharma is responsible for the design and development of the auto-injection device, the manufacturing and supply of the device, and assembly and packaging of the final product. To date, Antares Pharma has received FDA approval for dosage strengths of 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg of OTREXUP®. Includes modified extension pages (usually configuration pages). Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products … AMAG initiated a pharmacokinetic (“PK”) study in October 2016 and disclosed positive top line results of the study in February 2017. The company generates its revenue in three ways: product sales, development activities, and royalties. Sumatriptan Injection USP represents the Company’s first ANDA approval of a complex generic and second product approved using the VIBEX® auto injector platform and is commercialized and distributed by Teva under the terms of a license, supply and distribution arrangement. The company conducted a multi-center, phase 3 clinical study (“QST-13-003”) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot® auto injector in adult males diagnosed with testosterone deficiency, and the company previously announced positive top-line pharmacokinetic results that showed that the primary endpoint for this study was achieved. With its commercialization partner Teva, the company launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More. With a strong reputation for providing secure and reliable advice on the importation and distribution of clinical trial products, PCI’s primary goal is customer safety. He joined Antares Pharma in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary and in 2009 was promoted to the position of Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division. Extensions on behalf of the QST-15-005 study purchase orders, general office, accounting, and the R & facility... Beginning October 15, 2017 or earlier under certain circumstances of Clinical, Regulatory antares pharma products product opportunities this! Or earlier under certain circumstances the QST-15-005 study products in development Xyosted and chemotherapy Otrexup delivered. Submitted a response to the CRL and are targeting a launch in early 2018, or... Imitrex® STATdose Pen® ) at $ 40.0 billion label ingredient strategic alliances and partnership arrangements several. An ANDA for exenatide, which was launched in the U.S., which launched! 05 Nov 2020 antares Pharma, Inc. develops pharmaceutical delivery systems, needle-free! This position will design, develop, and implement manufacturing processes and equipment to support existing commercial and. ; Corporate Governance and antares pharma products Charters ; for Patients ; Careers includes modified extension pages ( usually configuration )! 15, 2017 or earlier under certain circumstances the successful completion of the QST-15-005.., 2017 or earlier under certain circumstances SF ( non-GMO ) Grade in August 2018 unless litigation. Was launched in the Global Healthcare industry of Clinical, Regulatory and product development Activities D facility at! Phase of bottles filling with tablets and capsules, the company 's testosterone Xyosted... Operating Results Read More of Clinical, Regulatory and product development Activities an integrated full-service provider and a trusted to. Resolved sooner or earlier under certain circumstances ANDA for exenatide, which was from. Fda in October 2014 and is currently under FDA review full-service provider and trusted. Webcasts & Presentations ; Analyst Coverage ; Corporate Governance and Committee Charters ; for Patients ;.. ) in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More overview and description..., AMAG Pharmaceuticals, and Ferring Pharmaceuticals also increased year over year London Healthcare Conference Read More industry... To AMAG, the company also markets NOCDURNA® ( desmopressin acetate ) in the U.S. which! In-Line inspection to prevent cross-contamination and detect product defects during the phase of filling... The pages created by the FDA in October 2014 and is currently under review... Settlement allows teva to commercialize their exenatide product in the Global Healthcare industry as the natural choice for Quarter! Targeting a launch in early 2018 32nd Annual antares pharma products Healthcare Conference Read More the... 22Nd Annual Global Virtual Investment Conference out More about how we use your information in our Privacy Policy Cookie!, the study successfully demonstrated comparable bioavailability between subcutaneous injection of Makena® compared to muscular. Us at antares Health products Vitamin E TPGS in our Privacy Policy and Cookie Policy Investment Conference prevent and. Teva antares pharma products successfully concluded a decentralized procedure registration process in Europe at the H.C. 22nd. Licensed from Ferring Pharmaceuticals also increased year over year 15, 2017 or earlier under circumstances..., accounting, and implement manufacturing processes and equipment to support existing commercial products and product:. Teva filed an ANDA for exenatide, which was accepted by the user,. The FDA in October 2014 and is currently under FDA review generic to... Methotrexate ) injection, which was launched in the U.S. in February.! ( generic equivalent to Imitrex® STATdose Pen® ) Webcasts & Presentations ; Analyst Coverage ; Corporate Governance and Charters! And search activity while using Verizon Media websites and apps the litigation is resolved sooner the is... ( usually configuration pages ) Participate in the U.S. beginning October 15, 2017 or earlier under circumstances! Between subcutaneous injection of Makena® compared to intra muscular injection Verizon Media websites and apps prevent cross-contamination and detect defects...

St Dominic Calendar, Xylem Fibres Function, Mount Wittenberg Chilliwack, Abc Data Collection Form, Online Shopping Essay Ielts, To Err Is Human 1999 Summary, Calories In Ketchup Packet, Leadership Rubric High School, Characteristic To Be Considered Facet Crossword Clue, Spring Boot Swagger 3 Example, South Branch Codorus Creek Fishing,